Diamyd Medical announced today that the company's 4-year follow-up of type 1
diabetes patients included in the company's Phase II study shows a clear
positive trend.
Diamyd Medical received approval from the Swedish Medical Products
Agency in
February to follow up the children and adolescents with type 1
diabetes that
were included in the company's previously reported Phase II
study with the
diabetes vaccine Diamyd®. The participants were treated
with 2 injections of
Diamyd® or placebo; one injection at the study start
in 2005 and one injection
one month later. Initial analysis of new data
shows, that patients treated with
the Diamyd® vaccine early after diagnosis
have a clearly better diabetes status
compared to the corresponding placebo
group, still 4 years after the injections.
Also safety data continue to look
good without any serious side effects related
to the treatment. The patients
will additionally be followed regarding Quality
of Life and diabetes
complications. The study period is 7 years. All
participants in
the study were offered to participate in the follow-up and
approximately
two thirds have accepted.
“This is
extremely promising,” says Elisabeth Lindner, CEO and President of
Diamyd
Medical. “We have already shown that the vaccine has managed to
significantly change the course of diabetes in Diamyd® -treated patients. The
fact that two single injections still seem to have an effect 4 years later
is to
be regarded as very good news.”
Diamyd Medical is conducting a global Phase III program for the
Diamyd® diabetes
vaccine, which includes a total of 640 children and
adolescents newly diagnosed
with type 1 diabetes. The program comprises one
study involving nine European
countries and one parallel study in the US.
The purpose of the Phase III studies
is to confirm and evaluate the ability of
the Diamyd® vaccine to halt or slow
the autoimmune destruction of the
body's insulin-producing cells, thereby
preserving the body's own
ability to produce insulin in people with type 1
diabetes.
For additional
information, please contact:
Elisabeth
Lindner, President and CEO Diamyd Medical AB (publ.)
Tel:
+46 (0)8 661 0026
For pictures and press material, please contact:
Andreas Ericsson, Diamyd Medical AB (publ.)
andreas.ericsson@diamyd.com
Tel:+46 (0)8 661 0026
About Diamyd Medical
Diamyd Medical is a Swedish diabetes company focusing on
the development of pharmaceuticals for the treatment of
autoimmune diabetes and
its complications. The company's most advanced
project is the GAD-based drug
Diamyd® for type 1 diabetes. Phase III
trials for this drug are in progress in
both Europe and the US. In addition,
the company has initiated clinical studies
in the US in the area of chronic
pain, using its Nerve Targeting Drug Delivery
System (NTDDS). The company
has also out-licensed the use of GAD for the
treatment of Parkinson's
disease. The company currently has three clinical-phase
products.
Diamyd Medical has
offices in Sweden and in the US. Shares are listed on Nasdaq
OMX in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY)
administered
by the Pink OTC Markets and the Bank of New York Mellon (PAL).
Further
information is available on the company's website: www.diamyd.com.
This
information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements
stated in the listing agreements.
Diamyd Medical AB (publ.)
Linnégatan 89 B,
SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46
(0)8 661 63 68
E-mail: info@diamyd.com. VAT no: SE556530-142001.
(www.omxnordicexchange.com
ticker: DIAM B; www.otcqx.com ticker: DMYDY)
|